Created at	Source	Raw Value	Validated value
June 4, 2022, 2 p.m.	usa	Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Percentage of seroconversion.;Safety: Adverse reactions.;Safety: Laboratory evaluations	Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Percentage of seroconversion.;Safety: Adverse reactions.;Safety: Laboratory evaluations
Aug. 8, 2021, 3 p.m.	usa	Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Percentage of seroconversion.;Safety: Adverse reactions.	Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Neutralization GMT SARS-CoV-2 pseudovirus.;Immunogenicity: Percentage of seroconversion.;Safety: Adverse reactions.